Alnylam Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
The page includes a questions and answers table for Alnylam Pharmaceuticals Inc. This Disclosure score includes 17 UN Sustainable Development Goals including: 'Affordable & Clean Energy', 'Industry, Innovation & Infrastructure' and 'Life on Land'. This webpage is a zero-cost Environmental, Social and Governance assessment for Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.2; made up of an environmental score of 4.6, social score of 4.6 and governance score of 8.0.
6.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 563 | ReproCell Inc | 6.3 | High |
| 563 | Venus Remedies Ltd | 6.3 | High |
| 586 | Alnylam Pharmaceuticals Inc | 6.2 | High |
| 586 | Althea Group Holdings Ltd | 6.2 | High |
| 586 | AlzeCure Pharma AB | 6.2 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Alnylam Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc report the average age of the workforce?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc offer flexible work?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc conduct supply chain audits?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose water use targets?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Alnylam Pharmaceuticals Inc have a product recall in the last two years?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Alnylam Pharmaceuticals Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose parental leave metrics?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Alnylam Pharmaceuticals Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose its waste policy?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc report according to TCFD requirements?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose energy use targets?
Sign up for free to unlockDoes Alnylam Pharmaceuticals Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Alnylam Pharmaceuticals Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Alnylam Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.